Dr. Chantal Guillemette holds a Canada Research Chair in pharmacogenomics. She is a Professor at the Faculty of Pharmacy at Laval University and co-director of the Cancer Research Center (CRC) at Laval University.

Dr. Guillemette is one of the leaders in the field of the pharmacogenomics of phase II enzymes, with a focus on glucuronidation by UDP-glucuronosyltransferase enzymes (UGTs). Her international leadership comes from ground breaking discoveries in precision oncology that positioned her lab at the forefront of the global research on the most important pathway for the human body’s elimination of frequently prescribed drugs, also regulating hormonal drivers of cancer. Dr. Guillemette, along with her coworkers and external collaborators, have significantly advanced several areas of drug metabolism and cancer biomarkers. She has published over 130 papers, the majority as a senior author and her students as first authors. She also offers a productive, creative and dynamic training environment (>125 high qualified personnel) supported by a strong record of trainees (>60) and future scientists while educating undergrads and health professionals in pharmacology and personalized medicine. Her work has improved our understanding of the mechanisms contributing to variations in biotransformation by UGTs, and how this affects drug response and disease. This led to knowledge translation strategies for the clinical use of genetic information on drug metabolism by UGTs. Her work has also extended to the discovery of cancer predisposing genes and more recently, to the discovery of new prognostic markers uncovered for hormone-related cancers such as prostate cancer.

Her focus is now on two objectives well integrated with clinical unmet needs in high-incidence cancers (leukemia, prostate and lung) to address the mechanisms underlying variability in anticancer drugs and steroid metabolism and how this affects patients’ responses, disease progression and patients’ survival. A first objective comprehensively investigates the molecular mechanisms that underlie variability in anticancer drugs and steroid metabolism by UGTs using complementary models that integrate research on genomics, splicing and post-translational processes using cutting-edge technologies. These findings will greatly contribute to achieve the required mechanism-based evidence to propel progress in the field and their potential clinical applications, with an impact on a larger set of prescribed drugs and broad clinical settings. A second objective aims to establish, through translational studies of patients diagnosed with high-incidence cancers, the clinical implications of variability in steroid and anticancer drug metabolism pathways. Genetic, hormonal and pharmacological markers will be tested as part of predictive tools that can identify individuals more likely to suffer adverse reactions to novel anticancer substrates of UGTs and those who are more likely to respond to therapy. We also address how variability in steroid and drug metabolism pathways can help improve prognostic signatures for recurrence and cancer patient’s survival after initial treatment. This research is reinforced by a strong and efficiently balanced collaborative network of scientists supported by the active roles of clinicians. This research has the potential to improve personalization of oncology treatment and prognostication for frequent cancers.

CHUL
2705, boulevard Laurier
R-4701.5
Québec, Québec
Canada G1V 4G2
175 entries « 1 of 18 »

Rouleau M, Villeneuve L, Allain EP, McCabe-Leroux J, Tremblay S, Nguyen Van Long F, Uchil A, Joly-Beauparlant C, Droit A, Guillemette C

Non-canonical transcriptional regulation of the poor prognostic factor UGT2B17 in chronic lymphocytic leukemic and normal B cells

Journal Article

BMC Cancer, 24 (1), 2024.

Abstract | Links:

Lafront C, Germain L, Campolina-Silva GH, Weidmann C, Berthiaume L, Hovington H, Brisson H, Jobin C, Frégeau-Proulx L, Cotau R, Gonthier K, Lacouture A, Caron P, Ménard C, Atallah C, Riopel J, Latulippe É, Bergeron A, Toren P, Guillemette C, Pelletier M, Fradet Y, Belleannée C, Pouliot F, Lacombe L, Lévesque É, Audet-Walsh É

The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression

Journal Article

J Clin Invest, 2024.

Abstract | Links:

Peters BA, Hanna DB, Wang Y, Weber KM, Topper E, Appleton AA, Sharma A, Hodis HN, Santoro N, Guillemette C, Caron P, Knight R, Burk RD, Kaplan RC, Qi Q

Sex Hormones, the Stool Microbiome, and Subclinical Atherosclerosis in Women With and Without HIV

Journal Article

J Clin Endocrinol Metab, 109 (2), 2024.

Abstract | Links:

Rouleau M, Nguyen Van Long F, Turcotte V, Caron P, Lacombe L, Aprikian A, Saad F, Carmel M, Chevalier S, Lévesque E, Guillemette C

Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancer

Journal Article

Br J Cancer, 128 (2), 2023.

Abstract | Links:

Lacombe L, Hovington H, Brisson H, Mehdi S, Beillevaire D, Émond JP, Wagner A, Villeneuve L, Simonyan D, Ouellet V, Barrès V, Latour M, Aprikian A, Bergeron A, Castonguay V, Couture F, Chevalier S, Brimo F, Fazli L, Fleshner N, Gleave M, Karakiewicz PI, Lattouf JB, Trudel D, van der Kwast T, Mes-Masson AM, Pouliot F, Fradet Y, Audet-Walsh E, Saad F, Guillemette C, Lévesque E

UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways

Journal Article

Cancer Lett, 553 , 2023.

Abstract | Links:

Dahmani C, Caron P, Simonyan D, Lacombe L, Aprikian A, Saad F, Carmel M, Chevalier S, Lévesque E, Guillemette C

Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate Cancer

Journal Article

J Urol, 209 (2), 2023.

Abstract | Links:

Wagner A, Rouleau M, Villeneuve L, Le T, Peltier C, Allain ÉP, Beaudoin C, Tremblay S, Courtier F, Nguyen Van Long F, Laverdière I, Lévesque É, Banerji V, Vanura K, Guillemette C

A Non-Canonical Role for the Glycosyltransferase Enzyme UGT2B17 as a Novel Constituent of the B Cell Receptor Signalosome

Journal Article

Cells, 12 (9), 2023.

Abstract | Links:

Dahmani C, Caron P, Simonyan D, Turcotte V, Grégoire J, Plante M, Guillemette C

Circulating adrenal 11-oxygenated androgens are associated with clinical outcome in endometrial cancer

Journal Article

Front Endocrinol (Lausanne), 14 , 2023.

Abstract | Links:

Nguyen Van Long F, Valcourt-Gendron D, Caron P, Rouleau M, Villeneuve L, Simonyan D, Le T, Sergerie R, Laverdière I, Vanura K, Guillemette C

Untargeted metabolomics identifies metabolic dysregulation of sphingolipids associated with aggressive chronic lymphocytic leukaemia and poor survival

Journal Article

Clin Transl Med, 13 (12), 2023.

Abstract | Links:

Wu Z, Trabert B, Guillemette C, Caron P, Bradwin G, Graubard BI, Weiderpass E, Ursin G, Langseth H, McGlynn KA

Prediagnostic Hormone Levels and Risk of Testicular Germ Cell Tumors: A Nested Case-Control Study in the Janus Serum Bank

Journal Article

Cancer Epidemiol Biomarkers Prev, 32 (11), 2023.

Abstract | Links:

175 entries « 1 of 18 »
Signaler des ajouts ou des modifications

En tant que titulaire de la Chaire de recherche du Canada en pharmacogénomique, Chantal Guillemette poursuit trois principaux objectifs à long terme. Tout d’abord, elle tente de déterminer les marqueurs génétiques qui permettent de maximiser la réponse aux médicaments tout en limitant les effets secondaires associés à certaines pharmacothérapies du cancer. Elle analyse ensuite les caractéristiques des tumeurs, ce qui lui permet de définir les processus moléculaires liés à la réponse ou à la résistance au traitement.

En second lieu, la chercheure entend identifier des biomarqueurs génétiques ou biochimiques qui permettraient de déceler rapidement le cancer et les patients qui sont les plus susceptibles d’en être atteints. Enfin, l’objectif de Mme Guillemette vise à favoriser une meilleure compréhension des fonctions et des effets des variations génomiques, ce qui pourrait permettre d’intégrer la pharmacogénomique dans les études cliniques et permettre un transfert de connaissances plus rapide en clinique afin de maximiser et de personnaliser la pharmacothérapie.

Active projects

  • Association of Sex Steroid Hormones and Gallbladder Cancer in Women, from 2023-09-29 to 2025-03-28
  • Chaire de recherche du Canada en pharmacogénomique, from 2020-10-01 to 2027-09-30
  • Effect of environmental contaminants and methylome of breast adipose tissue on aromatase inhibitor efficacy in breast cancer, from 2016-07-01 to 2024-09-30
  • Functional pharmacogenomics of cancer : from mechanisms to personalized therapy, from 2019-07-01 to 2026-06-30
  • Investigate novel markers of kidney injury in children requiring a cardiac surgery, from 2023-12-20 to 2024-12-19
  • Projet portant sur les hormones stéroïdiennes et le cancer de la prostate, from 2023-09-01 to 2027-08-31
  • Targeting sex steroids to improve the response to bladder cancer immunotherapy, from 2021-10-01 to 2026-09-30
  • Une infrastructure IA multi-usagers clé en main pour gérer le cycle de vie complet des données en santé, from 2021-04-01 to 2024-06-30

Recently finished projects

  • Deep phenotyping of UGT human knockouts, from 2023-03-01 to 2024-02-29
  • Identifying selective glucuronidation inhibitors to overcome drug resistance in cancer, from 2020-06-01 to 2022-05-31
  • Understanding the variations in clinical presentations of endometriosis: a pan-Canadian cohort study, from 2023-03-01 to 2024-02-29
Data provided by the Université Laval research projects registery